您的浏览器版本太低,将不能正常浏览。请升级 Internet Explorer或使用Google Chrome浏览器。
如果您在使用双核浏览器,请切换到高速 / 极速 / 神速 核心。
Location: Home > Advantage > Core Competence
Strict quality system

Referring to the quality management concept of multinational enterprises from the beginning of its establishment, the quality system has been established by employing the former senior manager of GSK R&D quality who has many years'experience in foreign enterprises. The company's management is committed to creating a "quality first" corporate culture within the company, always adhering to the quality policy of full participation, continuous improvement and high-quality service, and gradually established a sound quality management system to ensure that the drug research and development process and results are true, compliant, scientific and consistent. From July to August 2018, the company passed the quality audits of Johnson & Johnson & Johnson and Fesenyuskabi Pharmaceuticals. After two audits, two groups of experts fully affirmed the company's perfect quality system. Both groups of experts believe that the management level of the company's quality system has reached the quality system requirements of Europe and the United States and other countries, and laid a solid foundation for the company to cooperate with large multinational enterprises and domestic enterprises aspiring to carry out Sino-US double-newspaper business cooperation. In November 2018, the company's project HQ-0003 successfully passed the on-site verification of the State Drug Administration. From the inspection results, the company's quality management level meets the requirements of the State Drug Administration.

Management Team with Multinational Enterprise Background

Most of the company's managers are from Johnson & Johnson, GlaxoSmithKline, Pfizer, TEVA, SGS and other multinational enterprises, with rich management and technical experience.

R&D team dominated by foreign scientists

The company has introduced a technical team of generic drug development from India and other countries, focusing on the development of oral sustained and controlled release preparations.


CONTACT
CMC Service Manager Yan 86-132-8008-6176
Email:yanyali@hq-pharma.com
Clinical Services Manager Li 86-132-80640-394
Email:liminmin@hq-pharma.com
HR Ms.Kong
86-183-6997-3236(Zibo)
Ms.Wu
86-153-0177-9963(Shanghai)
Email:hr@hq-pharma.com